These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 967232)

  • 21. An evaluation of the hot plate technique to study narcotic antagonists.
    Heilman RD; Gray MI; Chen RP; Hahn EF; Fishman J
    Res Commun Chem Pathol Pharmacol; 1976 Apr; 13(4):635-47. PubMed ID: 1265343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting narcotic antagonist complexes.
    Gray AP; Guardina WJ
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):21-6. PubMed ID: 1234981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat.
    Yoburn BC; Cohen AH; Inturrisi CE
    J Pharmacol Exp Ther; 1986 Apr; 237(1):126-30. PubMed ID: 3958962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-acting narcotic antagonist complexes.
    Gray AP; Guardina WJ
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):21-6. PubMed ID: 967231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The development of sustained action preparations of narcotic antagonists.
    Willette RE
    NIDA Res Monogr; 1978; (19):333-9. PubMed ID: 218109
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute and chronic effects of naltrexone and naloxone on schedule-controlled behavior of squirrel monkeys and pigeons.
    Goldberg SR; Morse WH; Goldberg DM
    J Pharmacol Exp Ther; 1981 Mar; 216(3):500-9. PubMed ID: 7205630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants.
    Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson RC
    Addict Biol; 2004 Mar; 9(1):67-72. PubMed ID: 15203441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
    Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological evaluation of narcotic antagonist delivery systems in rhesus monkeys.
    Harrigan SE; Downs DA
    NIDA Res Monogr; 1981; 28():77-92. PubMed ID: 6791015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained release injectable naltrexone microcapsules.
    Nuwayser ES; DeRoo DJ; Balskovich PD; Tsuk AG
    NIDA Res Monogr; 1990; 105():532-3. PubMed ID: 1908558
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine.
    Ward SJ; Portoghese PS; Takemori AE
    J Pharmacol Exp Ther; 1982 Mar; 220(3):494-8. PubMed ID: 6121045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biodegradable gentamicin-depot implants made of beta-tricalcium phosphate ceramics. 3. In vivo studies on drug release, tissue tolerance, and biodegradation].
    Thoma K; Alex R; Randzio J
    Pharmazie; 1991 Apr; 46(4):266-70. PubMed ID: 1715996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interactions between narcotic agonists, partial agonists and antagonists evaluated by schedule-controlled behavior.
    Harris RA
    J Pharmacol Exp Ther; 1980 Jun; 213(3):497-503. PubMed ID: 6110766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants.
    Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson R; O'Neil P
    Addict Biol; 2004 Mar; 9(1):59-65. PubMed ID: 15203440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade.
    Bashaw ED; Kaiko RF; Grandy RP; Reder RF; Goldenheim PD
    Int J Clin Pharmacol Ther; 1995 Sep; 33(9):524-9. PubMed ID: 8520812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
    Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
    J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composites.
    Yolles S; Leafe TD; Woodland JH; Meyer FJ
    J Pharm Sci; 1975 Feb; 64(2):348-9. PubMed ID: 1127596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice.
    Medina Jiménez M; Luján Estrada M; Rodríguez R
    Arch Med Res; 1997; 28(1):61-5. PubMed ID: 9078589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological characterization of supersensitivity to naltrexone in squirrel monkeys.
    France CP; Morse WH
    J Pharmacol Exp Ther; 1989 Sep; 250(3):928-36. PubMed ID: 2550622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases.
    Brewer C
    Addict Biol; 2002 Jul; 7(3):321-3. PubMed ID: 12126492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.